Effect of sodium–glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus

BACKGROUND: Asprosin, a novel adipokine that raises glucose levels and stimulates appetite, has been proved to be pathologically increased in populations predisposed to type 2 diabetes mellitus (T2DM), obesity, and cardiovascular diseases. The mechanisms of sodium-glucose co-transporter-2 (SGLT2) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Aijun, Feng, Zhanrong, Yuan, Lu, Zhang, Ying, Li, Qian, She, Yuqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992350/
https://www.ncbi.nlm.nih.gov/pubmed/33766125
http://dx.doi.org/10.1186/s13098-021-00652-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992350/
https://www.ncbi.nlm.nih.gov/pubmed/33766125
http://dx.doi.org/10.1186/s13098-021-00652-5

Ejemplares similares